Structured evidence table for Peppermint Oil Bloating Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Peppermint Oil Bloating Randomized Trial | Young adults, particularly females, have a higher prevalence, which has increased substantially over the past decades []. | 2 | Pastras Ploutarchos (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines |
| Peppermint Oil Bloating Randomized Trial | More specifically, the presence of recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: symptoms related to defecation, a change in stool frequency, or a change in stool form []. | 2 | Pastras Ploutarchos (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines |
| Peppermint Oil Bloating Randomized Trial | IBS is associated with reduced engagement in daily activities, increased work absenteeism, and impaired functioning, thereby increasing the global healthcare burden []. | 2 | Pastras Ploutarchos (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines |
| Peppermint Oil Bloating Randomized Trial | 1 2 1 3 1 4 5 Disorders of gut–brain interaction (DGBIs) are functional gastrointestinal conditions characterized by a complex interplay between the gut and the brain []. | 2 | Pastras Ploutarchos (2026) | Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines |
| Peppermint Oil Bloating Randomized Trial | 1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities []. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
| Peppermint Oil Bloating Randomized Trial | Early studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,]. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
| Peppermint Oil Bloating Randomized Trial | Moreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
| Peppermint Oil Bloating Randomized Trial | It affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources []. | 3 | Šuran Jelena (2026) | IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions |
Source documents